Top Stories
The company said its oral PK activator still has potential as a next-generation treatment for sickle-cell disease, where Phase II topline data are due next half.
Phase II/III study of the mezigdomide regimen showed consistent benefit across high-risk subgroups, though severe neutropenia increased markedly.
The deal includes antibody-drug conjugates with unique payloads and multi-specific antibodies with differentiated immune-engaging features.
An FDA panel recommended seasonal COVID-19 vaccines target the XFG variant, while Sanofi's venglustat and Beren's adrabetadex now have November PDUFA dates.
The label expansion comes about a year after the FDA approved AstraZeneca's PD-L1 inhibitor for patients with cisplatin-eligible muscle-invasive bladder cancer.
Conference News
Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated diseaseConsistent responses observed across atypical...
Patients had a 55% likelihood of remaining alive without disease progression at seven years, and median progression-free survival was not reached with LORBRENAUpdated follow-up analysis solidifies LO...
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...
Leveraging AI, trained on one of the industry’s largest clinical trial datasets, Medidata delivers quantifiable evidence to improve breast cancer trial enrollment and evaluate the efficacy of tocilizu...
MIAMI, May 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 di...
